Tectonic Therapeutic, INC Form 4 insider transactions

Peter McNamara, Chief Scientific Officer of Tectonic Therapeutic, reports the acquisition of common stock and stock options following the merger with AVROBIO, Inc.

Daniel Lochner, CFO of Tectonic Therapeutic, Inc., reports the acquisition of 118,000 employee stock options.

Christian Cortis, Chief Operating Officer of Tectonic Therapeutic, reports the acquisition and conversion of common stock and stock options following the merger with AVROBIO, Inc.

Alise Reicin, CEO of Tectonic Therapeutic, reports the acquisition of common stock and stock options following the merger with AVROBIO, Inc.

AVROBIO, Inc. is supplementing disclosures related to its merger with Tectonic Therapeutic, Inc. to address stockholder lawsuits and demands alleging misrepresentations and omissions in the registration statement.

Tectonic Therapeutic appoints Daniel Lochner as Chief Financial Officer, effective June 3, 2024, in anticipation of the merger with AVROBIO.

AVROBIO is urging its shareholders to vote in favor of the proposed merger with Tectonic Therapeutic at the upcoming Special Meeting on June 11th.

AVROBIO is urging its shareholders to vote in favor of the proposed merger with Tectonic Therapeutic at the upcoming Special Meeting of Stockholders on June 11, 2024.

Braden Michael Leonard, a director and 10% owner of AVROBIO, Inc., has increased his indirect holdings through purchases made by BML Investment Partners, L.P.

AVROBIO and Tectonic Therapeutic are set to merge, backed by a $130.7 million private financing, to focus on developing novel GPCR-targeted therapies with a cash runway into mid-2027.